RevolKa, a venture-backed biotech company, has just elevated its financial position with a significant boost of Y250m ($1.7m) in Series A extension funding, setting the stage for a rapid acceleration of its drug discovery programmes. This funding round not only supports RevolKa’s financial fortitude but also underscores the potential of its innovative approach to drug […]
Tag: Series A
Vivodyne Revolutionizes Clinical Testing with $40M Funding
In the biopharmaceutical realm, the harsh reality is a staggering 95% failure rate in human clinical trials, despite promising results in animal testing. However, a rising star in the industry, Vivodyne, is poised to confront this formidable challenge head-on, armed with $40 million in Series A financing and a revolutionary approach to preclinical testing. Vivodyne […]
